Last reviewed · How we verify

NCT04675320: IMMUNOPARP

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

Status unknown Last updated 7 December 2023
What this trial tests

trial testing blood samples in Ovarian Cancer in 50 participants. Status unknown.

Timeline
7 July 2020
Primary endpoint
10 November 2022
10 November 2024

Quick facts

Lead sponsorCentre Georges Francois Leclerc
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date7 July 2020
Primary completion10 November 2022
Estimated completion10 November 2024
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Georges Francois Leclerc — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study concerns the creation of a biological collection (blood samples) in patients with Epithelial Ovarian Cancer in in order to describe the immune response with PARP inhibitors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The war between the immune system and the tumor - using immune biomarkers as tracers.
    Yang K, Lu R, Mei J, Cao K, et al · · 2024 · cited 9× · PMID 38816871 · DOI 10.1186/s40364-024-00599-5

Verify or expand the search:

Other trials of blood samples

Trials testing the same drug.

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

Other Centre Georges Francois Leclerc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04675320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing